Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Genitourinary Malignancies
share announcement

Genitourinary Malignancies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 15 August 2024 | Viewed by 843

Special Issue Editor

Dr. Dominick Bosse

E-Mail Website
Guest Editor
Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada
Interests: chemotherapy; medical oncology; renal cell carcinoma; prostate cancer; transitional cell carcinoma; germ cell tumors; hepatocellular carcinoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Genitourinary malignancies, including prostate, bladder, kidney, and testicular cancers, are at the forefront of innovation, with a continuous influx of novel therapeutics reshaping treatment paradigms. Although the pipeline of new therapeutics continues to evolve, achieving the ultimate goal of personalized medicine proves challenging. The scarcity of reliable biomarkers predicting responses or toxicities to cancer treatments has prompted the development of several drug combinations which ultimately improve outcomes. Nevertheless, the introduction of these combinations, coupled with numerous recent changes in frontline treatments, has intensified the complexity of treatment selection and sequencing, as well as the optimization of toxicity management and quality of life.

This Special Issue welcomes manuscripts addressing the unknowns surrounding treatment optimization, the development of predictive markers, the refinement of therapy sequencing, and the strategies to improve and prevent drug toxicity as well as patients’ quality of life.

Dr. Dominick Bosse
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genitourinary malignancy
  • renal cell carcinoma
  • prostate cancer
  • urothelial cancer
  • germ cell tumor
  • outcomes
  • toxicities
  • quality of life
  • markers
  • treatment sequencing

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 823 KiB  
Article
Magnetic-Resonance-Imaging-Guided Cryoablation for Solitary-Biopsy-Proven Renal Cell Carcinoma: A Tertiary Cancer Center Experience
by Mohamed E. Abdelsalam, Nabeel Mecci, Ahmed Awad, Roland L. Bassett, Bruno C. Odisio, Peiman Habibollahi, Thomas Lu, David Irwin, Jose A. Karam, Surena F. Matin and Kamran Ahrar
Cancers 2024, 16(10), 1815; https://doi.org/10.3390/cancers16101815 - 10 May 2024
Viewed by 541
Abstract
Background: Our purpose is to evaluate the long-term oncologic efficacy and survival rates of MRI-guided cryoablation for patients with biopsy-proven cT1a renal cell carcinoma (RCC). Materials and Methods: We retrospectively reviewed our renal ablation database between January 2007 and June 2021 and only [...] Read more.
Background: Our purpose is to evaluate the long-term oncologic efficacy and survival rates of MRI-guided cryoablation for patients with biopsy-proven cT1a renal cell carcinoma (RCC). Materials and Methods: We retrospectively reviewed our renal ablation database between January 2007 and June 2021 and only included patients with solitary-biopsy-proven cT1a RCC (≤4 cm) who underwent MRI-guided cryoablation. We excluded patients with genetic syndromes, bilateral RCC, recurrent RCC or benign lesions, those without pathologically proven RCC lesions and patients who underwent radiofrequency ablation or CT-guided cryoablation. For each patient, we collected the following: age, sex, lesion size, right- or left-sided, pathology, ablation zone tumor recurrence, development of new tumor in the kidney other than ablation zone, development of metastatic disease, patient alive or not, date and cause of death. We used the Kaplan and Meier product limit estimator to estimate the survival outcomes. Results: Twenty-nine patients (median age 70 years) met our inclusion criteria. Twenty-nine MRI-guided cryoablation procedures were performed for twenty-nine tumor lesions with a median size of 2.2 cm. A Clavien–Dindo grade III complication developed in one patient (3.4%). Clear cell RCC was the most reported histology (n = 19). The median follow up was 4.5 years. No tumor recurrence or metastatic disease developed in any of the patients. Two patients developed new renal lesions separate from the ablation zone. The 5- and 10-year OS were 72% and 55.6%, respectively. The 5- and 10-year DFS were 90.5% and the 5-year and 10-year LRFS, MFS and CSS were all 100%. Conclusions: MRI-guided cryoablation is a safe treatment with a low complication rate. Long-term follow-up data revealed long-standing oncologic control. Full article
(This article belongs to the Special Issue Genitourinary Malignancies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop